189 research outputs found
D-Chiro-Inositol and LPS Induce a PCOS-Like Hyperandrogenic Response in Human KGN Granulosa Cells
No full textHyperandrogenism is a key hallmark of polycystic ovary syndrome, a prevalent endocrine disorder affecting women of reproductive age and often leading to infertility. We previously observed that high doses of D-chiro-inositol in mice reduce ovarian aromatase expression, contributing to a hyperandrogenic state. Given that similar effects have been reported in tumour-derived human KGN granulosa cells treated with bacterial lipopolysaccharide, we investigated whether D-chiro-inositol could elicit a comparable hyperandrogenic response in these cells, thereby shedding light on aberrant mechanisms potentially involved in polycystic ovary syndrome. Using lipopolysaccharide and myo-inositol as controls, we assessed KGN cells for proliferation, viability, inflammatory response, cellular and mitochondrial reactive oxygen species, expression of antioxidant enzyme genes, aromatase expression, and estradiol secretion. None of the treatments affected cell proliferation or viability. Both D-chiro-inositol and myo-inositol showed anti-inflammatory and antioxidant effects, whereas lipopolysaccharide induced inflammation and acted as a pro-oxidant. Notably, D-chiro-inositol and lipopolysaccharide downregulated aromatase gene and protein expression, resulting in reduced estradiol secretion. In contrast, myo-inositol had no significant impact on aromatase expression or oestrogen production. These findings suggest that D-chiro-inositol and lipopolysaccharide may serve as useful tools for probing the dysregulated molecular and cellular pathways associated with polycystic ovary syndrome, particularly those contributing to hyperandrogenism
On the origin of paramagnetic inhomogeneity effects in blood.
No full textHydrogen, sodium, and fluorine (added F-) NMR spectra of venous and oxygenated blood were measured. The fluorine resonance was seen as a single peak in both samples, and all three resonances exhibited the same deoxy-oxy shift. Because F- exchanges slowly across the red cell membrane, and because sodium is 95% extracellular, these results suggest that the intra-extracellular field difference delta B is less than 0.1 ppm. A small value of delta B tends to rule out transmembrane exchange as an important contributor to relaxation in MRI of blood and hematomas. However, the broadening of the resonances with deoxygenation, by 0.3-0.4 ppm, indicates that both intra- and extracellular gradients are of comparable and sufficient magnitude to produce the T2-weighted hypointensity seen in clinical magnetic resonance images of hematomas at high fields
Micrometastasi del midollo osseo in un paziente con carcinoma della prostata : evidenza clinica di differenziazione neuroendocrina
No full textModificazioni dei livelli sierici del PSA durante blocco androgenico intermittente in pazienti con progressione dopo prostatectomia radicale
No full textValore della ploidia e delle dimensioni del tumore come indici di progressione tumorale nel carcinoma renale localizzato
No full textIntermittent androgen deprivation in patients with localized prostate cancer and a biochemical progression after radical prostatectomy
No full textFra febbraio 1994 e maggio 1996, sono stati selezionati 34 pazienti successivi con iniziale progressione del PSA dopo prostatectomia radicale retropubica. Tutti i soggetti avevano un adenocarcinoma prostatico localizzato pT2NpN0M0. I pazienti sono stati trattati con IAD quando il PSA superava valori di 0,4 ng/ml. La durata del trattamento iniziale con Blocco Androgenico Totale (BAT) è stata di 24 settimane in tutti i casi. Successivamente, un nadir accettabile del PSA era considerato un valore ≤ 0,4 ng/ml. La terapia con BAT veniva ripresa per valori di PSA > 0,4 ng/ml.
L’intervallo di follow-up è stato di 144 fino a 228 settimane. Il tempo mediano per i primi 5 cicli di trattamento è stato rispettivamente di 32, 24, 28, 32 e 32 settimane, con un tempo mediano di “off-therapy” che aumentava da 8 settimane (primo ciclo) a 22 settimane (quinto ciclo). Il nadir mediano del PSA durante il periodo di “on therapy” era 0.20 ng/ml in tutti i cicli terapeutici. La IAD potrebbe essere una terapia efficace nei pazienti con progressione iniziale di PSA dopo chirurgia, tuttavia follow-up maggiori sono necessari per poter supportare tale schema terapeutico
Deprivazione androgenica intermittente in pazienti con progressione biochimica dopo prostatectomia radicale:influenza del Gleason score
No full text
Carcinoma a cellule renali associato co altri tumori primitivi in organi bersaglio di ormoni steroidei .Influenza della storia riproduttiva e dei fattori ormonali
No full text- …
